
|
|
|
|
|
|
Comments: DURHAM, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it has submitted a Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) seeking approval of the Human Acellular Vessel (HAV) in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and when autologous vein use is not feasible. The BLA submission is supported by positive results from the V005 Phase 2/3 clinical trial as well as from the treatment of wartime injuries in Ukraine. The HAV was observed to have higher rates of patency (blood flow), and lower rates of amputation and infection, as compared to historic synthetic graft benchmarks. “Submitting the BLA to the FDA is a pivotal milestone in achieving our goal of providing regenerative human tissues to injured patients, at commercial scale,” said Laura Niklason, MD, PhD, Chief Executive Officer of Humacyte. “I want to thank the patients and medical professionals who participated in our clinical studies, and our Humacyte, team for their tremendous effort and dedication in completing the BLA submission for this first-in-class product candidate.” The FDA has a 60-day review period to determine whether the BLA is complete and acceptable for filing. Humacyte has requested Priority Review of the application and, if granted, the review should be completed within six months of the filing acceptance date. In May 2023 the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for use of the HAV in urgent arterial repair following extremity vascular trauma. In addition, the HAV was assigned a priority designation by the Secretary of Defense under Public Law 115-92, enacted to expedite the FDA’s review of products that are intended to diagnose, treat or prevent serious or life-threatening conditions facing American military personnel, such as traumatic injuries.
Comments: این یک سری رو خیلی اذیت کرده. ![]() https://youtu.be/9qvoYobDR58
Comments: The support is definitely disgusting.
Comments: آقا رضا کاملا موافقم. وجدان صفر.
Comments: This was a wake up call for US, you can’t continue to be on the wrong side of history and claim we just made a mistake. This is why I have zero tolerance for those fucking ignoramus iranian here that support Israel. They disgust me.
Comments:
Comments: Agha Zinsky, let me know your decision.
Comments: Do you know when FDA is scheduled to review this?
Comments: Zinsky, you promised not to. ![]() The fact that FDA will do priority review is very promising though. If the company gets approval, its stock will go well over $10, may be $15.
Comments: Like last year, we are having rain, almost weekly. This is such a change compared to the years before last!
Comments: Thanks for the info. Stock is at $4 and change. I’m tempted!!!🤫
Comments: I do not know anything about this. But a few thoughts: 1. Manufacturing these engineered vessels has been done before. The big challenge is the immune response that they cause. If this will be dependent of whether the body will accept or reject this, then there will be a lot of doubt. Given that they have done a level 2 and 3 trial, I suspect that they have some data on this. May be this is not an issue or that the issue is not as severe as previous models. 2. I was hoping that this would be used in patients with CVD. But it looks like it is more for injuries. If they can expand this to CVD, the company will explode beyond any other Biotech company. This seems not on their radar (at least publicly).
Comments: Any insight into this? Humacyte gains on FDA priority review for bioengineered blood vessel
Comments: That was you? Nice job 👍 🤣
Comments: The one doing the cool tricks.
Comments: Reza: "One points a gun at him while he is collapsed on the ground, screaming in pain." ![]() ![]()
Comments: "some scenes from our Sunday game" Which one is you?
Comments:
Comments: Well, winter seems to be over here. It wasn't a real one to begin with, but we are getting some high 50s and low 60s coming up. I am not complaining or anything, but this is the 2nd winter that wasn't!
Comments: An active-duty member of the U.S. Air Force set himself on fireoutside the Israeli Embassy in Washington, D.C., on Sunday to protest Israel's war in Gaza, according to reports and video posted on social media. Aaron Bushnell, 25, died after being transported to a local hospital on Sunday afternoon, a spokesperson for the Metropolitan Police Department (MPD) told Newsweek via email. "My name is Aaron Bushnell, I am an active-duty member of the United States Air Force and I will no longer be complicit in genocide," he says in a video of the incident. "I am about to engage in an extreme act of protest, but compared to what people have been experiencing in Palestine at the hands of their colonizers, it's not extreme at all. This is what our ruling class has decided will be normal." The video shows Bushnell walk up to the driveway of the Israeli embassy, set his phone down on the ground and pour an unknown liquid from a bottle over himself and ignite it while yelling, "Free Palestine" repeatedly. That officer's gun remains drawn as another sprays him with a fire extinguisher. "I don't need guns, I need fire extinguishers!" one officer is heard yelling as other officers arrive on the scene. The fire had already been extinguished by the U.S. Secret Service when firefighters arrived at the scene, D.C. Fire and EMS said in a post on X, formerly Twitter. The MPD spokesperson said that officers had responded at around 1 p.m. to assist the Secret Service. The department is working with the Secret Service and the Bureau of Alcohol, Tobacco, Firearms and Explosives to investigate the incident, the spokesperson added. The Air Force said Bushnell was a cyber defense operations specialist with the 531st Intelligence Support Squadron at Joint Base San Antonio. He had served on active duty since May 2020. "When a tragedy like this occurs, every member of the Air Force feels it," Col. Celina Noyes, commander the 70th Intelligence, Surveillance and Reconnaissance Wing, said. "We extend our deepest sympathies to the family and friends of Senior Airman Bushnell." Independent reporter Talia Jane wrote on X that Bushnell's loved ones gave consent for a blurred version of the video to be posted online. The page describes him as an "aspiring software engineer" with "a talent and passion for solving complex problems with code." It says: "Throughout my time in the military in both leadership and followership roles, as well as prior work experience in a variety of civil roles, I have thrived in team environments and gained very good communication skills." He was pursuing a bachelor's degree in software engineering at Western Governor's University, according to the page. He previously studied software development at Southern New Hampshire University and computer science at the University of Maryland Global Campus. Bushnell's protest comes as Israel's war on Hamas has killed about 30,000 Palestinians, The Associated Press reported, citing the Health Ministry in Gaza. Israel declared war following the Hamas attack on southern Israel on October 7, in which about 1,200 people were killed. Israel's air and ground offensive has since driven about 80 percent of Gaza's population from their homes. |
| < Previous 20 | Next 20 > |